The 2026 cohort, selected by a BioSpace committee, includes leaders such as Strand Therapeutics CEO Jake Becraft, Mammoth Biosciences co-founder Trevor Martin, and CG Oncology CEO Arthur Kuan. These professionals were nominated between July and August, meeting strict criteria that required them to hold leadership roles within U.S.-based companies. According to Josh Goodwin, CEO of BioSpace, this group represents the next generation of biopharma, demonstrating a tangible impact on patient outcomes and operational excellence.
In section Releases
BioSpace Names 2026 Cohort for 40 Under 40 Leadership List
From AI-driven drug discovery to patient advocacy and corporate strategy, 40 emerging professionals have been recognized by BioSpace for their contributions to the life sciences sector. The annual list highlights individuals under 40 who are currently steering innovation across biotech startups, global pharmaceutical firms, and contract manufacturing organizations.
Beyond the executive ranks, the list features specialists in biology, data science, and business development from organizations ranging from Bristol Myers Squibb and Genentech to specialized innovators like Maze Therapeutics and Scribe Therapeutics. The full roster of honorees includes Ioana Aanei, James Andorko, Victoria Assimon, Kaggen Ausma, Shruthi Bharadwaj, Calvin Chan, Bob Chen, Eddie Chung, Pedro Coelho, Beryl Cummings, Mehul Desai, Josh Haimson, Louisa Helms, Michelle Ho Huey, Ben Hohl, Lex Johnson, Anastasiia Kamenska, Amy Kauffman, William Leonardi, Klevin Lo, Sophia Lugo, Blake Mandell, Narbe Mardirossian, Saber Meamardoost, Kimberly Nettles, Haichen Nie, Kanwal Palla, Nindhana Paranthaman, Morgan Paull, Matthew Pierce, Samantha Piteri-Molina, Caitlin Prendes, Zvonimir Vrselja, Hannah Walter, Qing Yu Christina Weng, Johnny Yu, and Christine Zhang.
Comments (0)
No comments yet. Be the first!